Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218432 · ClinicalTrials.gov registry record · NA
A Study of the TheraBionic P1 Device in Breast Cancer
A NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07218432 is a NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 24 participants, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07218432, a NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
Conditions Studied
Interventions
- DEVICE TheraBionic P1 Device
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218432
The ClinicalTrials.gov registry entry for NCT07218432 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which TheraBionic P1 Device is the first listed.
NCT07218432 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07218432 about?
NCT07218432 is a clinical study titled "A Study of the TheraBionic P1 Device in Breast Cancer". The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
What is the current status of trial NCT07218432?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-10. Estimated completion is 2028-06-30.
What conditions does trial NCT07218432 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage I, Hormone Receptor Positive Tumor, Breast Cancer Stage IIIA.
What interventions are being tested in trial NCT07218432?
The interventions under investigation include: TheraBionic P1 Device (DEVICE).
Who is sponsoring clinical trial NCT07218432?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218432 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.